You are here:

Home
NICE Guidance
Conditions and diseases
Musculoskeletal conditions
Arthritis

Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis

Technology appraisal guidance
Reference number: TA199
Published: 25 August 2010

Guidance
Tools and resources
Information for the public
Evidence
History

Expert comments on the ACD

Dr Eleanor Korendowych
Dr Philip Helliwell
Revisions to the cost effectiveness analysis after the committee meeting of 16 February 2010
Revisions to the cost effectiveness analysis following comments from consultees on 2 February 2010

This page was last updated: 08 June 2010